November 22nd 2024
ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data
View More
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
EnVision Summit
February 14-17, 2025
Register Now!
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Triamcinolone monotherapy loses favor as potential AMD treatment
February 21st 2006In the new treatment era for exudative age-related macular degeneration (AMD) heralded by the availability of locally administered anti-VEGF drugs, intravitreal monotherapy with triamcinolone injection may no longer be considered as a current therapy for this neovascular condition, said Jost Jonas, MD, at the World Ophthalmology Congress.
Risk factors for wet AMD revisited
February 20th 2006Age-related macular degeneration (AMD) is a common cause of vision loss worldwide, particularly in industrialized nations, where it is the main cause of blindness among people of 65 and older, explained Paul Mitchell, MD, at the World Ophthalmology Congress.
Novartis happy as Lucentis shows further promise in AMD
January 1st 2006Novartis Ophthalmics' and Genentech's investigational treatment for AMD has again delighted its developers by meeting its one-year primary efficacy endpoint of maintaining vision in patients with wet AMD during the first year of the two-year ANCHOR study.
Wet AMD: Is combination therapy the way of the future?
October 1st 2005Despite recent advances and the promise of new therapies for the treatment of choroidal neovascularization (CNV) resulting from age-related macular degeneration (wet AMD), key challenges remain. These include improving vision outcomes, reducing the numbers of treatments and proving efficacy in different lesion types. While treatment for wet AMD has traditionally centred on monotherapy regimens, the future standard of care may likely focus on combination strategies.
Follow-up injection with intravitreal triamcinolone improves PDT outcomes
October 1st 2005Combination treatment of neovascular age-related macular degeneration (AMD) using verteporfin photodynamic therapy (Visudyne PDT, Novartis/QLT Inc.) plus intravitreal triamcinolone acetonide appears to improve visual outcomes and reduce the number of re-treatments necessary to achieve lesion regression compared with standard PDT alone, albeit with the recognized steroid-associated risks of cataract progression and IOP elevation, said Albert J. Augustin, MD, at the annual meeting of the American Society of Retina Specialists.